Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone by Jacob, Joanna C et al.
                          Jacob, J. C., Poklis, J. L., Akbarali, H. I., Henderson, G., & Dewey, W. L.
(2017). Ethanol Reversal of Tolerance to the Antinociceptive Effects of
Oxycodone and Hydrocodone. Journal of Pharmacology and Experimental
Therapeutics, 362(1), 45-52. https://doi.org/10.1124/jpet.117.241083
Early version, also known as pre-print
Link to published version (if available):
10.1124/jpet.117.241083
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via ASPET at http://jpet.aspetjournals.org/content/362/1/45 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
 
Title Page 
 
Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone  
by 
Joanna C Jacob1, Justin L Poklis1, Hamid I Akbarali1, Graeme Henderson2 and William L Dewey1* 
1. JJ, JP, HA, WD: Department of Pharmacology and Toxicology, Virginia Commonwealth University, 
1112 East Clay Street, Richmond, Virginia, 23298-0613, USA 
2. GH: School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol BS8 1TD, UK  
 
 
 
 
 
 
 
 
 
 
2 
 
Running Title Page 
Running Title: Ethanol Reversal of Oxycodone and Hydrocodone Tolerances 
*Author for correspondence:  
William L. Dewey  
Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, 
Richmond, Virginia, 23298-0613, USA, 
Phone:  804-827-0375 
Email: william.dewey@vcuhealth.org 
 
Text pages – 31 
Tables – 1 
Figures – 5 
References – 33 
Abstract – 239 
Introduction – 670 
Discussion – 1308 
Section: Neuropharmacology 
 
 
 
3 
 
Abstract 
This study compared the development of tolerance and its reversal by ethanol of two orally-
bioavailable prescription opioids, oxycodone and hydrocodone, to that of morphine. Oxycodone 
(s.c) was significantly more potent in the mouse tail withdrawal assay than either morphine or 
hydrocodone. Oxycodone was also significantly more potent in this assay than hydrocodone when 
administered orally. Tolerance was seen following chronic subcutaneous administration of each of 
the three drugs and by the chronic administration of oral oxycodone, but not following the chronic 
oral administration of hydrocodone. 1 g/kg i.p. ethanol significantly reversed the tolerance that 
developed to the subcutaneous administration of each of the three opioids. It took twice as much 
ethanol when given orally to reverse the tolerance to oxycodone. We investigated whether the 
tolerance observed to oxycodone and its reversal by ethanol were due to bio-dispositional changes 
or were reflecting a true neuronal tolerance. As expected, a relationship between brain oxycodone 
concentrations and activity in the tail immersion test existed following administration of acute oral 
oxycodone. Following chronic treatment, brain oxycodone concentrations were significantly lower 
than acute concentrations. 2 g/kg oral ethanol reversed the tolerance to chronic oxycodone, but did 
not alter brain concentrations of either acute or chronic oxycodone. These studies show that there 
is a metabolic component of tolerance to oxycodone, however the reversal of that tolerance by 
ethanol is not due to an alteration of the bio-disposition of oxycodone, but rather is neuronal in 
nature. 
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Introduction  
Prescription opioids such as oxycodone were responsible for over half of the reported 28,000 
opioid overdose deaths in 2014 (CDC, 2016). Individuals who abuse prescription opioids often 
use other substances leading to poly-drug abuse (Ogbu et al., 2015). Ethanol is one of the most 
commonly co-abused drugs by opioid users, despite the long-standing warning that ethanol and 
opioids pose a significant health risk when taken together (Karch and Drummer, 2001; Oliver et 
al., 2007). Multiple post-mortem analyses have shown that individuals who consumed opioids 
such as heroin along with alcohol died from blood opioid concentrations measuring significantly 
below than those who died from an opioid without alcohol consumption (Darke and Hall, 2003). 
Additionally, a separate study that specifically investigated oxycodone-related overdoses reported 
that deaths resulting from the combined intake of oxycodone and ethanol were ruled to be 
exclusively accidental, rather than intentional (Thompson et al., 2008). While it is possible that a 
general lack of awareness exists among opioid users regarding the dangers related to co-
consumption of ethanol with opioids, it is likely that these individuals experience some 
enhancement of opioid effects when used together, leading to riskier drug taking behavior to offset 
the tolerance(s) developed to the opioids. Post-mortem studies reported findings from blood levels 
extracted from peripheral sites such as the femoral artery and heart blood. Collection of post-
mortem blood is easy to obtain and samples are reliably quantified, however it is important to 
recognize that the lethal event during opioid overdose is respiratory depression – a centrally-
mediated effect controlled primarily in the brainstem where opioid receptor density is quite high 
(Delfs et al., 1994; Satoh and Minami, 1995).  One hypothesis relating to the increased lethality 
of oxycodone when ethanol was also detected in presumed opioid-tolerant individuals, is that 
ethanol is altering the kinetics of oxycodone. Therefore, it was important to investigate if in fact 
the distribution and concentration of oxycodone in the brain is altered by ethanol administration.  
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 Ethanol is also known to reverse various tolerances to morphine, including the 
antinociceptive and respiratory depressive effects, which may be explained by mechanisms that 
involve PKC and GABAA and GABAB receptor signaling (Hull et al., 2013; Hill et al., 2016). 
Additionally, recent evidence has shown that ethanol was unable to reverse the respiratory 
depressive tolerance to methadone, suggesting that certain opioids may be more susceptible to 
ethanol’s reversal effects than others (Withey et al., 2017). Our goal for the studies presented here 
was to compare the effects of ethanol reversal as seen previously in morphine tolerant mice to 
those of mice made tolerant to two other commonly abused opioids, oxycodone and hydrocodone, 
to determine if they are more “morphine-like” or more “methadone-like” in regards to their 
interaction with ethanol.  
These drugs, like morphine and heroin, have been shown to exert their analgesic and 
respiratory depressive effects through similar pathways and mechanisms involving the µ-opioid 
receptor. There are a number of unique properties belonging to oxycodone and hydrocodone, 
however, that set them apart from morphine beyond slight structural differences, such as varying 
degrees of oral bioavailability and their primary enzymatic degradation pathways (Reisine and 
Pasternak, 1996; Kolesnikov et al., 2003). Discrepancies exist in the literature regarding which 
opioid receptor mediates oxycodone’s antinociceptive effects, with studies carried out in rats 
supporting a primary role of the kappa receptor based on in vitro binding studies and behavioral 
assessments (Nielsen et al., 2007). Studies utilizing in vitro and in vivo approaches in mice 
however, showed the µ-opioid receptor is the primary receptor type that is preferentially bound 
and activated by oxycodone (Yoburn et al., 1995). Additionally, it was shown that in the tail flick 
assay, neither NorBNI nor naltrindole, the k opioid receptor and δ opioid receptor antagonists 
respectively, were unable to block the antinociceptive properties of oxycodone (Beardsley et al., 
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2004). Given the differences underlying the pharmacodynamics and pharmacokinetics of these 
opioid compounds, it was of interest to determine if ethanol reversed analgesic tolerance to both 
of these compounds, and to what degree each of the compounds were susceptible to ethanol’s 
reversal effects.  
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Materials and Methods 
Drugs and Chemicals. Morphine sulfate, Oxycodone HCl, Hydrocodone bitartrate and 75-mg 
morphine pellets and placebo pellets were obtained from the National Institutes of Health National 
Institute on Drug Abuse (Bethesda, MD). Morphine sulfate, Oxycodone HCl and Hydrocodone 
bitartrate were each dissolved in pyrogen-free isotonic saline (Hospira, Lake Forest, IL). Ethanol 
was obtained from AAPER Ethanol and Chemical Co. (Shelbyville, KY) and was diluted with 
pyrogen-free isotonic saline.  
Animals. Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25–30 g 
were housed five to a cage in animal care quarters and maintained at 22 ± 2°C on a 12-hour light-
dark cycle. Food and water were available ad libitum. The mice were brought to the test room (22 
± 2°C, 12-hour light-dark cycle), marked for identification, and allowed 18 hours to recover from 
transport and handling. Protocols and procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Virginia Commonwealth University Medical Center and comply 
with the recommendations of the International Association for the Study of Pain (IASP). 
Tail Immersion Test. The warm-water tail immersion test was performed using a water bath with 
the temperature stabilized at 56 ±  0.1°C (Coderre and Rollman, 1983). Before injecting the mice, 
a baseline (control) latency was determined. Only mice with a control reaction time between 2 to 
4 seconds were used. Test latencies were assessed 20 minutes following opioid treatment, with a 
10-second maximum cut-off time utilized to prevent tissue damage.  Antinociception was 
quantified as the percentage of maximum possible effect (%MPE), which was calculated as:  
%MPE = [(test latency – control latency) / (10 – control latency)] X 100. Percent MPE was 
calculated for each mouse using at least six mice per dose of drug (Harris and Pierson, 1964).  
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Acute Dose Response Curves in Tail Immersion Test: Oxycodone, Hydrocodone and 
Morphine. Male Swiss Webster mice were weighed and baseline tail withdrawal latencies were 
recorded as described above. Oxycodone was administered subcutaneously at doses of 0.25, 0.5, 
1.0, 1.25 and 1.5 mg/kg and mice were returned to their home cage. Hydrocodone was 
administered subcutaneously at doses of 1.0, 3.0, 5.0 and 6.0 mg/kg and mice were returned to 
their home cage. Morphine was administered subcutaneously at doses of 2.0, 4.0, 8.0, and 16 
mg/kg and mice were returned to their home cage. After a 20-minute pretreatment period, mice 
were re-tested for tail withdrawal latencies to assess antinociceptive effects and to conduct dose-
response curves.  
Single-Day Tolerance Model. Antinociceptive tolerance to oxycodone and hydrocodone was 
developed as follows. Mice were injected subcutaneously (s.c.) once every hour (for a total of 
seven injections) with the respective ED80 dose of each opioid corresponding to the tail immersion 
test, 1.25 mg/kg for oxycodone and 5.0 mg/kg for hydrocodone, and saline in control mice. One 
hour after the final injection, mice were administered 1 g/kg ethanol or 0.9% saline vehicle by 
intraperitoneal (i.p.) injection and 30 minutes later were challenged with various subcutaneous 
doses of oxycodone (ascending log2 doses from 0.25 – 4.0 mg/kg) or hydrocodone (ascending log2 
doses from 1 – 16 mg/kg) to construct dose-response curves for calculation of ED50 values and 
potency ratios. 
4-day Tolerance Model. Tolerance to oral oxycodone or hydrocodone was developed using a 
twice-daily gavage method whereby animals were administered 64 mg/kg oxycodone, or 128 
mg/kg hydrocodone, in the morning and again in the evening, with at least 8 hours separating the 
two gavage events. Animals were weighed on day 1, 3 and 5 (test day) and dosing was adjusted 
accordingly. The evening gavage administration on day 4 was the final maintenance dose animals 
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received prior to test and challenge treatments on day 5. Drug dose was calculated for 0.1cc/10g 
body weight administration with 0.9% physiological saline as the vehicle. All mice had continued 
access to ad libitum food and water throughout the dosing paradigm and remained group-housed 
in their home cages.  
Oral Oxycodone Time Course. A time course study was conducted to assess the antinociceptive 
effects of oral oxycodone following a single gavage of 16 mg/kg oxycodone at the following time 
points: 5, 10, 20, 30, 60, 120, 240 and 480 minutes. Here, 5 mice were repeatedly tested to 
determine average %MPE at each time point. Utilizing the same time points and dose of 
oxycodone, we repeated the time course study to assess brain oxycodone concentrations. An N of 
5 mice per time point was utilized for the brain concentration analysis.  
Reagents for GC/MS Analysis. The primary reference materials of morphine, morphine-d3, 
oxycodone and oxycodone-d6 were purchased from Cerilliant Corporation (Round Rock, Texas) 
as metabolic solutions.  The chloroform, deionized (DI) water, hydroxamine hydrochloride (HCL), 
2-propanol, sodium bicarbonate and sodium carbonate were purchased form Fisher Scientific 
(Hanover Park, Illinois). BSTFA (N,O-bis(trimethylsilyl)-trifluoroacetamide) + 10% TMCS 
(Trimethylchlorosilane) was purchased from Regis Technologies (Morton Grove, Illinois). 
Sample Extraction. Quantitative analysis of morphine and oxycodone was based upon a 
previously described method (Broussard et al., 1997; Wolf and Poklis, 1997). This method is 
routinely preformed in our laboratory for the analysis of opiates in blood and tissue samples. Pre-
extraction preparation was unnecessary for the whole blood specimens. Whole brain tissues 
specimens were diluted as 1 part tissue to 3 parts deionized water (v:v) and homogenized.  Matched 
matrix five-point calibration curve containing opiates of interest were prepared at 20-1000 ng/mL 
for blood  or 20-1000 ng/g for tissue, along with a blank and a double blank controls.  10 µL of 
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internal standard (ISTD) consisting of 10 µg/mL (100 ng total) of morphine-d3 and oxycodone-d6 
was added to 1.0 mL or 1.0 g aliquots of calibrators, controls and specimens, except the double 
blank control.  0.2mL of 10% hydroxamine HCL was added to each sample. They were then mixed 
and heated at 30°C for 30 mins. Samples were then cooled and 1 mL of saturated carbonate/ 
bicarbonate buffer (1:1, N:N, pH 9.5) and 2 mL of chloroform:2-propanol (8:2) were added.  
Samples were mixed for 5 min and then centrifuged at 2500 rpm for 5 min.  The top aqueous layer 
was aspirated and the organic layer was transferred to a clean test tube and evaporated to dryness 
at 40°C under a constant stream of nitrogen. 50 µL of BSTFA (N,O-bis(trimethylsilyl)-
trifluoroacetamide) + 10% TMCS (Trimethylchlorosilane) was added and the samples were heated 
for 30 min at 70°C.  The samples were then placed in auto-sampler vials for gas chromatography 
mass spectrometry (GC/MS) analysis. 
Instrumental Analysis. The GC/MS analysis was performed with a Hewlett-Packard 6890 with a 
split/splitless injection port attached to Hewlett-Packard model 5793A mass selective detector 
(MSD) with a 7683 autosampler.  The chromatographic separation was preformed on an Agilent 
(Santa Clara, California) HP-1 12 m x 0.2mm x 0.33 µm analytical column with the injection 
temperature set to170°C in run in pulsed splitless mode.  The initial oven temperature was 170°C 
and was held for 1.0 min., then heated at 10°C/min. to 280°C. The total run time was 12 min.  The 
quantification and qualifying ions monitored for were for morphine 236, 414 and 429 m/z; for 
oxycodone 269, 459 and 474 m/z; for morphine-d3 239 and 432 m/z; and for oxycodone-d6 465 
and 480 m/z.  A linear regression of the ratio of the peak area counts of quantification ion of ISTD 
versus concentration was used to construct the calibration curves. 
Data Analysis. Opioid dose response curves were conducted for calculation of ED50 values by 
the method of Bliss (1967), utilizing least-square linear regression analysis followed by 
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calculation of 95% confidence limits (Bliss, 1967). For all other statistical analyses, GraphPad 
Prism 5 was used (GraphPad Software, Inc., La Jolla, CA). All data are represented as mean ± 
standard error of the mean. A One-way ANOVA with Tukey’s post-hoc analysis was utilized 
when comparing changes across three or more groups over a single factor. Statistical differences 
between only two groups of data were analyzed using Student’s two-tailed unpaired t-test. 
Significant differences were considered when P < 0.05.  
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Results 
Acute Effects of Oxycodone and Hydrocodone. 
To test acute antinociceptive properties, oxycodone or hydrocodone was administered 
subcutaneously and assessed in the warm water tail withdrawal test. Tail withdrawal latencies 
dose-dependently increased, reaching a ceiling effect at 1.5 mg/kg for oxycodone and at 6.0 mg/kg 
for hydrocodone, where all animals exhibited an MPE of 100%. The ED50 value for acute 
oxycodone was calculated to be 0.84 mg/kg (0.68 – 1.04). The ED50 value for hydrocodone was 
calculated to be 3.95 mg/kg (2.40 – 6.52). Morphine was administered subcutaneously with all 
mice reaching 100% MPE at 8 mg/kg. The ED50 was calculated to be 3.94 mg/kg (3.55 – 4.36).  
As predicted, we found that oxycodone was more potent than hydrocodone, which was equally as 
potent as morphine when administered subcutaneously in mice.  
We then compared the potencies of oxycodone and hydrocodone when given orally, due to their 
reliable oral bioavailability. Acutely, oxycodone produced an oral ED50 of 9.29 mg/kg (7.18 – 
12.02), ten times its subcutaneous ED50 value. In subsequent experiments comparing chronic saline 
treated (i.e. control) versus chronic oxycodone treated mice, a similar ED50 value of 8.29 mg/kg 
(6.12 – 11.52) was obtained in the control mice, indicating acute oral oxycodone ED50 values are 
reliably reproducible (Table 1). Hydrocodone orally produced an ED50 value also nearing ten times 
the subcutaneous value, equaling 38.79 mg/kg (29.21 – 51.53) (Table 1).  
Tolerance Developed to Oxycodone and Hydrocodone Following Repeated Administration.  
Oxycodone Tolerance: Chronic injections of s.c. saline prior to s.c. oxycodone challenge doses 
yielded a dose response curve of oxycodone with an ED50 value of 0.90 mg/kg (0.72 - 1.12), 
reproducing what was observed in our acute dose response experiments, suggesting no adverse 
effects of handling or repeated vehicle injections on oxycodone’s antinociceptive effect. In mice 
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repeatedly administered s.c. oxycodone prior to receiving s.c. oxycodone challenge doses, the ED50 
value was 1.70 mg/kg (1.42 - 2.03), significantly shifted to the right compared to the mice that 
received chronic saline, indicating tolerance was observed (Figure 1A). We further characterized 
oxycodone tolerance development by investigating the response to repeated oral oxycodone. A 
modified protocol with repeated exposure across 4 days, rather than repeated exposure within a 
single day, was utilized for this experiment. We found a significant shift to the right in response to 
chronic oral oxycodone with an ED50 value of 33.41 mg/kg (25.50 – 44.17) compared to the acute 
ED50 value of 8.29 mg/kg (6.12 -11.52) reported above, demonstrating that these mice were 
tolerant to the antinociceptive effects of orally administered oxycodone.  
Hydrocodone Tolerance: Chronic s.c. injections of saline followed by acute challenge doses of s.c. 
hydrocodone generated a dose response curve with an ED50 value of 3.92 mg/kg (3.26 -4.71) 
(Figure 1B) in mice, similar to what was observed in previous acute dose response experiments as 
stated above. The ED50 value significantly shifted to the right in animals chronically injected with 
hydrocodone prior to receiving the challenge injections, equaling 9.01 mg/kg (6.44 – 12.62) and 
indicating tolerance developed in these mice. We also investigated the development of tolerance 
to oral hydrocodone and utilized a 4-day protocol similar to what was used for our chronic oral 
oxycodone studies. We observed an increase in the oral ED50 value, equaling 55.92 mg/kg (40.63 
– 76.96), however, the confidence limits overlap that of the acute oral ED50 value (38.79 mg/kg 
(29.21 – 51.53)), suggesting that complete tolerance was not observed in the oral dosing study 
(Table 1). In a follow-up study, we increased the maintenance dose to 256 mg/kg po and still did 
not observe tolerance to the antinociceptive effects of hydrocodone (data not shown).  
Reversal of Oxycodone and Hydrocodone Antinociceptive Tolerance by Ethanol (i.p.).  We 
tested 1 g/kg ethanol i.p. administration in mice repeatedly administered oxycodone or 
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hydrocodone. Previously, our lab determined that a dose of 1g/kg ethanol was inert in the warm 
water tail withdrawal test, but fully reversed morphine tolerance in mice (Hull et. al, 2013). ED50 
values were calculated from the resulting dose response curves and compared across three 
conditions: chronic saline followed by saline and acute opioid challenge, chronic opioid followed 
by saline and opioid challenge, and chronic opioid followed by ethanol and opioid challenge. A 
single injection of 1g/kg ethanol reversed antinociceptive tolerance to both oxycodone and 
hydrocodone (Figure 1A and 1B) as shown by the restoration of the ED50 values which closely 
resembled values observed in the acute dose response experiments (Table 1). These results add to 
our previous findings that ethanol reversed the analgesic tolerance to morphine, suggesting that 
ethanol may be interfering with a pathway common to some, but not all, opioids.  
Reversal of Oxycodone Antinociceptive Tolerance by Oral Ethanol. Mice were assessed for 
oxycodone tolerance and reversal by po ethanol in addition to ip ethanol, again utilizing the single-
day tolerance paradigm. Mice that were repeatedly injected with s.c. oxycodone and received a 
saline gavage displayed tolerance to the antinociceptive effects in response to a 1.25 mg/kg 
oxycodone s.c. challenge injection as shown by a significantly lower %MPE (10.25% ± 2.71) (P 
< 0.05, One-way ANOVA) when compared to acute oxycodone controls (50.98% ± 11.95). Mice 
that were repeatedly injected with s.c. oxycodone but received a 2 g/kg po ethanol gavage prior to 
receiving the challenge s.c. oxycodone injection continued to respond to oxycodone, displaying 
antinociceptive responses similar to that of both acute oxycodone treated mice and oxycodone-
treated mice that received 1 g/kg ethanol i.p. The %MPE values observed in both of these chronic 
oxycodone plus ethanol treatment groups displayed significantly higher %MPE values compared 
to that of the chronic oxycodone plus saline treatment group, P < 0.05 (2 g/kg ethanol po, 63.90% 
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± 16.88) and P < 0.01 (1 g/kg ethanol ip, 71.49% ± 11.83), (One-way ANOVA) (Figure 2). These 
data indicate that both i.p. and p.o. ethanol reversed oxycodone tolerance. 
Pharmacokinetic Studies 
 
Acute Oral Oxycodone Time Course: Antinociception and Brain Concentrations.  16 mg/kg 
p.o. oxycodone was detectable in the brain at the earliest time point measured of 5 minutes, 
averaging 80.2 ng/g, while antinociception was marginal at 10.14% MPE on average. Peak brain 
concentrations were observed at 20 and 30 minutes following oxycodone administration, 153.58 
ng/g and 153.24 ng/g respectively. Brain concentrations at these times were significantly higher 
than concentrations detected at 120 minutes (P < 0.05) and 480 minutes (P < 0.001) (One-way 
ANOVA). Significant antinociception was detected at the 20, 30 and 60 minute time points but 
not at the 5 minute time point ((P < 0.05 (20 min) and P < 0.001 (30, 60 min), One-way ANOVA). 
Peak antinociception, measured as 100% MPE, was not detected until 30 minutes following 
administration, and persisted until the 60 minute point. Antinociception at 20 (P < 0.05), 30 and 
60 minutes following oxycodone was significantly higher than 480 minutes (P < 0.0001), with the 
30 and 60 minute time points also significantly higher than at 240 minutes (P < 0.001, One-way 
ANOVA) Brain oxycodone concentrations at 60 minutes however were markedly lower, 
measuring on average closer to the 5 and 10 minute time points, though the antinociceptive effects 
were vastly greater. Notably, oxycodone was not detectable in any of the brain tissue samples 
tested 480 minutes (8 hours) after a single gavage and there was no antinociception at this time 
(Figure 3).  
Brain Oxycodone Concentrations Did Not Correlate With Antinociception. We compared 
brain concentrations of oxycodone when given orally versus subcutaneously using equianalgesic 
doses. 1.25 mg/kg s.c. and 16 mg/kg p.o. oxycodone both produced near 80% MPE. 1.25 mg/kg 
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s.c. oxycodone produced 74.48% MPE while 16 mg/kg po oxycodone produced 77.71% MPE. 
Brain oxycodone concentrations averaged 348.89 ng/g following subcutaneous administration, 
significantly higher than oral oxycodone concentrations which averaged 114.1 ng/g (p < 0.0001, 
Student’s two-tailed unpaired t-test). Our findings indicate that the antinociceptive effects of 
oxycodone are not directly correlated with brain oxycodone concentrations (Figure 4).     
Acute Brain Concentrations of Oxycodone After Oral Administration. Oxycodone was 
administered orally in ascending log2 doses ranging from 8 to 64 mg/kg to assess a dose response 
relationship for brain concentrations. Brain concentrations showed an average of 137.2 ng/g (N = 
5), 114.1 ng/g (N = 10), 312.4 ng/g (N = 5), and 731.2 ng/g (N = 14) 20 minutes following 
administration of 8, 16, 32 and 64 mg/kg oxycodone respectively. Significant differences were 
detected between the 64 mg/kg and 16 mg/kg doses (P < 0.01, One-way ANOVA), as well as 
between 64 mg/kg and the 8 mg/kg dose (P < 0.05, One-way ANOVA).  
Brain Concentrations of Oral Oxycodone After Repeated Administration. The development 
of oral oxycodone tolerance was carried out over 4 days via twice daily gavage administrations of 
64 mg/kg oxycodone. Mice were challenged on day 5 with a single gavage of 16 mg/kg oxycodone. 
Brain concentrations 20 minutes following the challenge gavage showed an average of 28.92 ng/g 
(N = 13). These concentrations were significantly lower than seen after acute 16 mg/kg at the 20 
minute time point (P < 0.0001) (Figure 5A).  
The Effect of Oral Ethanol on Brain Concentrations of Acute Oral Oxycodone. To determine 
if ethanol alters acute oxycodone brain concentrations, mice were pretreated with 2 g/kg ethanol 
30 minutes prior to receiving a gavage of 16 mg/kg oxycodone. Mice were sacrificed 20 minutes 
following oxycodone administration and brain samples were collected and processed immediately 
thereafter. After the oral administration of 2 g/kg ethanol, brain concentrations averaged 304.7 ± 
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90.8 ng/g. Brain oxycodone concentrations were not significantly altered by 2 g/kg acute ethanol 
as compared to acute oxycodone alone (P > 0.05, Student’s two-tailed t-test) (Figure 5B).   
The Effect of Ethanol on Chronic Oxycodone Brain Concentrations. To determine if ethanol 
altered chronic oxycodone brain concentrations, mice were repeatedly administered oxycodone 
twice daily for four days and pretreated on day 5 with a gavage of 2 g/kg ethanol 30 minutes prior 
to receiving a challenge gavage of 16 mg/kg oxycodone. Mice were sacrificed 20 minutes 
following oxycodone administration and brain samples were collected and processed immediately 
thereafter. Brain oxycodone concentrations following chronic oxycodone administration and the 
acute administration of 2 g/kg ethanol equaled 26.13 ± 3.45 ng/g (N = 8) (Figure 5C). Chronic 
oxycodone concentrations measured in the presence of ethanol were consistent with the chronic 
oxycodone samples measured in the absence of ethanol, providing supporting evidence that acute 
ethanol did not alter chronic oxycodone brain concentrations (P > 0.05, unpaired Student’s two-
tailed t-test).  
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Discussion  
Oxycodone and hydrocodone are two of the most commonly prescribed opioids for the 
relief of pain despite their untoward side effects including tolerance development and abuse 
liability. Presently, an opioid abuse epidemic exists, in part, due to numerous individuals becoming 
dependent on prescription opioids, who then switch to heroin. When alcohol is consumed 
simultaneously with heroin, the risk of overdose and death increases. This could be due to one 
drug potentiating or adding to the depressant effects of the other, or due to the reversal of the 
tolerances that have developed to the opioid. We have previously shown that ethanol reversed 
morphine tolerance. The goal of this study was to compare the acute potency, propensity to 
produce tolerance, and assess reversal of that tolerance to oxycodone and hydrocodone by ethanol. 
A second goal was to elucidate if the tolerance was reversed due to an alteration of 
pharmacokinetic parameters.  
Characterization of the Development of Oxycodone and Hydrocodone Antinociceptive 
Tolerance and the Effect of Ethanol on that Tolerance. Using a single-day injection schedule, 
mice were made tolerant to either oxycodone or hydrocodone. We found a 2-fold rightward shift 
in ED50 values in mice repeatedly injected with oxycodone. The doses we used produced similar 
levels of antinociception as seen in other studies, though a different outbred mouse strain (ICR) 
was used (Beardsley et al., 2004; Minami et al., 2009). Similarly, we found a 2-fold rightward 
shift in ED50 values in mice repeatedly injected with hydrocodone. Interestingly, our acute ED50 
values for hydrocodone are between values reported by two others studies that used the radiant 
heat tail flick assay rather than warm-water tail immersion. Kolesnikov et al., (2003) found an 
ED50 value of 1.37 mg/kg in Swiss Webster mice bred by a different vendor, while Navani and 
Yoburn (2013), calculated an ED50 value of 11 mg/kg in CD-1 mice.  
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Ethanol was similarly effective in reversing the antinociceptive tolerance to both 
oxycodone and hydrocodone when administered at 1 g/kg i.p. In previous studies, this dose was 
also effective at reversing analgesic tolerance and respiratory depressive tolerance to morphine 
(Hull et al., 2013; Hill et al., 2016). Further, 20mM in vitro ethanol reversed ex vivo morphine 
tolerance in the locus coeruleus of rats, suggesting that low-to-moderate ethanol doses reverse 
tolerance without eliciting effects acutely  (Llorente et al., 2013).  
Pharmacokinetic Analysis of Acute Oxycodone Time Course. We investigated the relationship 
between brain oxycodone concentrations and antinociceptive effects in mice. Previously, we have 
shown that there is a correlation between brain morphine concentrations and tail flick latencies 
(Patrick et al., 1975, 1978). Oxycodone was detected in brain tissue 5 minutes after the oral 
administration of 16 mg/kg, but antinociception was minimal. The concentration continued to 
increase until 20 minutes post gavage, where it remained steady for at least ten more minutes, 
indicating peak concentrations for this dose of oxycodone were present in the brain. Significant 
antinociception was observed 20 minutes following oxycodone administration, with maximal or 
near maximal effects lasting from 20 to 60 minutes. Given that oxycodone was administered orally, 
it is not surprising that peak concentrations were not detected sooner. Additionally, mice were not 
food restricted in these studies, and gastric emptying time could have altered or delayed the time 
to which oxycodone was actually absorbed and distributed through the liver and to the brain. In 
addition, at 60 minutes, oxycodone concentrations were lower, though not significantly, as 
compared to peak concentrations at 20 and 30 minutes. Between 30 minutes and 60 minutes, there 
was a 50% decrease in oxycodone concentrations. The antinociceptive effects between 30 and 60 
minutes however, did not change and continued to produce 100% MPE. This discrepancy between 
brain concentrations of oxycodone and the antinociceptive effect measured likely suggests the 
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presence of an active metabolite, however our study did not investigate which metabolite(s) 
contributed to our observation. Oxycodone was not detected in the brain 8 hours after mice were 
dosed and no antinociceptive effects were observed. 
Brain Concentrations of Oxycodone After Chronic Administration. In chronic oxycodone 
treated-mice, brain oxycodone concentrations following a challenge gavage of 16 mg/kg were 
significantly lower compared to those observed in brains of mice that only received a single 
administration of the same dose of oxycodone. The effect was consistent, as demonstrated by the 
minimal variability between sample values, suggesting a well-regulated mechanism underlies 
oxycodone tolerance and metabolism. It is possible that while initial variances in individual 
response are likely to occur upon acute exposure, highly regulated signaling events and selectively 
activated enzymatic pathways lead to more structured biological responses upon repeated 
exposure. These data also provide further insight into the potential mechanisms underlying 
oxycodone tolerance. There could be a significant upregulation of degradative enzymes leading to 
the development of metabolic tolerance, and warrants further investigation into this possible 
explanation. Additionally, the reduction in brain oxycodone concentrations after repeated 
administration could be a result of increased P-glycoprotein (P-gp) activity, a chaperone protein 
that actively transports drug molecules across the blood brain barrier. P-gp is well characterized in 
its effects on opioid agonists (Dagenais et al., 2004), yet there are opposing reports regarding P-
gp’s actions on oxycodone. One study showed P-gp’s ATP-ase activity was dose-dependently 
increased by acute oxycodone and was upregulated after chronic oxycodone in rats (Hassan et al., 
2007), however, another study showed that the P-gp inhibitor, PSC833, had no effect on 
oxycodone’s ability to enter and remain in the brain in rats (Bostrom et al., 2005). The 
contributions of the latter study’s findings are difficult to interpret given that PSC833 has been 
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shown to be less specific than previously thought (Mayer et al., 1997; Cvetkovic et al., 1999).  
Acute and Chronic Oxycodone Pharmacokinetics Unaffected by Ethanol Co-administration 
in Mice. One of our main objectives in this study was to better characterize the effect of doses of 
ethanol that are moderately intoxicating in humans on acute and chronic brain oxycodone 
concentrations in mice.  In our acute ethanol and acute oxycodone study we found that oral ethanol 
at a dose of 2 g/kg did not significantly alter oxycodone brain concentrations. It was of utmost 
importance to evaluate the effects of ethanol on brain oxycodone concentrations in chronic 
oxycodone treated mice in order to address the primary health concern of poly-drug abuse leading 
to opioid overdose. We tested 2 g/kg oral ethanol on chronic oxycodone brain concentrations. 
Somewhat unexpectedly, we observed that 2 g/kg ethanol did not significantly alter oxycodone 
brain concentrations. These results in brain tissue differ from blood results from multiple human 
post-mortem analyses, where the co-detection of ethanol corresponded with significantly lower 
opioid levels in the blood compared to those where only opioids were detected at time of death 
(Kerr et al., 2007; Darke, 2011). These data do however agree with and add to the previous 
observations in Hill et al (2016) where 0.3 g/kg ethanol ip did not alter morphine brain or plasma 
concentrations in mice while still reversing the tolerance to respiratory depression, suggesting that 
ethanol is not working through mechanisms that alter the kinetics of either of these opioids (Hill 
et al., 2016). Furthermore, our findings were the result of acute ethanol effects on oxycodone brain 
concentrations, whereas repeated ethanol treatments might alter those findings. The effects of 
repeated ethanol have been tested on morphine behavioral responses and [3H]-dihydromorphine 
binding in mice, where a change in affinity for striatal opioid receptors was observed after ethanol 
feeding (Tabakoff et al., 1981). Clearly, ethanol effects on opioid blood and brain concentrations 
in mice are dependent on treatment regimen and the specific opioid compound tested.  
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These studies show that there is a metabolic component underlying oxycodone tolerance, 
yet our results suggest the reversal of that tolerance by ethanol is not due to an alteration of the 
bio-disposition of oxycodone. We therefore conclude that ethanol reversal of oxycodone tolerance 
is mediated by specific neuronal mechanisms, and future experiments will be conducted to address 
this finding.   
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Figure Legends 
Figure 1. Ethanol reversal of oxycodone and hydrocodone tolerance. Ethanol fully reversed 
both oxycodone (A) and hydrocodone (B) tolerance at a dose of 1g/kg. Each data point is 
represented by a minimum of five mice and represented as mean ± SEM. Animals were injected 
once hourly with either saline or an ED80 dose of oxycodone or hydrocodone s.c. for six hours, 
followed by an i.p. injection of ethanol (1g/kg) or saline one hour later. 30 minutes later, various 
challenge doses of oxycodone or hydrocodone were injected s.c. to construct dose response curves 
and generate ED50 values. 
 
Figure 2. Intraperitoneal and oral ethanol reversed analgesic tolerance to s.c. oxycodone. 
Mice were chronically injected with s.c. oxycodone (1.25 mg/kg) or saline hourly for 6 hours and 
treated with saline, i.p ethanol (1 g/kg) or po ethanol (2 g/kg) prior to receiving a challenge 
injection of 1.25 mg/kg oxycodone. Antinociception was assessed using the tail immersion assay 
where significant tolerance was displayed in mice chronically treated with oxycodone and no 
ethanol, compared to the acute oxycodone treatment group (* P < 0.05, One-way ANOVA). Two 
additional groups of mice were treated with repeated injections of oxycodone, but received either 
an ip injection of 1 g/kg ethanol or a gavage of 2 g/kg ethanol 30 minutes prior to receiving an 
oxycodone challenge injection. Ethanol treatment in these mice reversed tolerance development 
to oxycodone as seen by a restored response to the antinociceptive effects of oxycodone. Chronic 
oxycodone treated mice given either ip ethanol († P < 0.01) or oral ethanol (‡ P < 0.05) displayed 
significantly greater antinociceptive effects in response to a challenge injection of oxycodone 
compared to chronic oxycodone mice given saline prior to an oxycodone challenge (One-way 
ANOVA). All groups are represented by a minimum of 5 mice with data shown as mean ± SEM.   
29 
 
Figure 3. Oral Oxycodone Time Course: Antinociception vs. Brain Concentration. After a 
single administration of 16 mg/kg oxycodone po, brain oxycodone concentrations were plotted 
against oxycodone’s antinociceptive effect in the warm water tail withdrawal assay at various time 
points ranging from 5 – 480 minutes. All data points represent mean ± SEM from a minimum of 
5 mice. Brain oxycodone concentrations increased during the first 20 minutes where a plateau was 
observed until 30 minutes. Antinociception was slower to reach 100% MPE, which was not 
observed until 30 minutes and persisted until 60 minutes. Brain oxycodone concentrations at 60 
minutes were much lower, measuring closer to the 5-minute time point, despite maximum 
antinociception. Significant observations for brain oxycodone concentrations were only noted at 
120 (†P < 0.05) and 480 (‡P < 0.001) minute time points (One-way ANOVA), where 
concentrations were lower than all other time points. Antinociception was significantly higher at 
20 (*P < 0.05), 30 and 60 minutes (***P < 0.001) compared to 5 minutes. Antinociception at 30 
and 60 minutes was significantly higher compared to 240 (P < 0.001) and 480 minutes (P < 0.0001). 
 
Figure 4. Brain Oxycodone Concentrations Do Not Correlate with Antinociceptive Effects of 
Oxycodone. Mice were injected or gavaged with the respective ED
80
 dose of oxycodone, 1.25 
mg/kg s.c. and 16 mg/kg po. Both doses produced equal antinociception in mice, however, brain 
oxycodone concentrations significantly differed, with much higher concentrations detected after 
subcutaneous administration (P < 0.0001, Student’s unpaired two-tailed t-test). A minimum of 5 
mice were used for each dose tested, with bars representing means ± SEM.   
 
Figure 5. Acute and Chronic Oxycodone Brain Concentrations. (A) Oxycodone brain 
concentrations 20 minutes following a challenge gavage of 16 mg/kg oxycodone in mice either 
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naïve to oxycodone or chronically treated with 64 mg/kg b.i.d. for four days. Acute concentrations 
represent the mean ± SEM of 10 mice, while chronic concentrations represent the mean ± SEM of 
13 mice. Brain oxycodone concentrations detected 20 minutes following the oxycodone challenge 
were significantly lower in mice chronically treated with oxycodone compared to that of acutely 
treated mice (****P < 0.001, Student’s two-tailed unpaired t-test). (B) The effects of 2g/kg ethanol 
were assessed against acute oxycodone brain levels. Each bar represents the mean ± SEM of at 
least 10 mice. Ethanol did not have had a significant effect (P > 0.05, Student’s unpaired two-tailed 
t-test) and both groups displayed similar brain oxycodone levels. (C) The effects of 2g/kg ethanol 
were assessed against chronic oxycodone brain levels. Ethanol did not have a significant effect (P 
> 0.05, Student’s unpaired two tailed t-test) and both groups displayed similar brain oxycodone 
levels in response to a challenge oxycodone gavage following chronic oxycodone treatment. Each 
bar represents the mean ± SEM of at least 8 mice. 
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TABLE 1 
Comparison of Tolerance Development and Ethanol Reversal of Various Opioid Compounds  
ED50s and 95% confidence limits were calculated under acute, chronic and chronic + ethanol 
conditions in mice. All opioids tested produced antinociceptive tolerance when repeatedly 
administered subcutaneously. Oxycodone and hydrocodone were also evaluated for oral 
antinociceptive potencies and tolerance development. Only oral oxycodone produced significant 
tolerance to itself after repeated administration. * denotes a significant shift from acute ED50 
values, determined by confidence limits that no longer overlap. 
 
 
 
 
 
 
 
 
 
 
 
 Morphine 
s.c. 
Oxycodone 
s.c. 
Oxycodone 
p.o. 
Hydrocodone 
s.c. 
Hydrocodone 
p.o. 
Acute ED50 
4.8 mg/kg 
(2.5 – 5.7) 
0.89 mg/kg 
(0.72 – 1.12) 
8.29mg/kg 
(6.12 – 11.52) 
3.92 mg/kg 
(3.26 – 4.71) 
38.79 mg/kg 
(29.21 – 51.53) 
Chronic ED50 
19.9 mg/kg* 
(14.8 – 29.1) 
1.70 mg/kg* 
(1.42 – 2.03) 
33.41 mg/kg * 
(25.50 – 44.17) 
9.01 mg/kg * 
(6.44 – 12.62) 
55.92 mg/kg 
(40.63 – 76.96) 
Chronic + 
Ethanol ED50 
5.2 mg/kg 
(4.9 – 5.5) 
1.02 mg/kg 
(0.77 – 1.37) 
35.52 mg/kg 
(20.19 – 59.03) 
4.73 mg/kg 
(3.51 – 6.38) 
N/A 
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